Anti-human CD19 (Clone: B43) | Recombinant, in vivo grade - Syd Labs

Catalog No.	Product Name	Size	List Price (US$)
PA007272.m2a	In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa	1 mg	200.00
PA007272.m2a	In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa	5 mg	500.00
PA007272.m2a	In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa	25 mg	1250.00

Catalog No.

Product Name

Size

List Price (US$)

Quantity

PA007272.m2a

In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa

1 mg

200.00

PA007272.m2a

In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa

5 mg

500.00

PA007272.m2a

In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa

25 mg

1250.00

Description

Background of Anti-human CD19 Monoclonal Antibody (Clone: B43)

The B43 antibody binds to the human CD19 protein, a transmembrane protein expressed in all B lineage cells including human plasma cells. CD19 plays two major roles in human B cells: it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies.

PA007272.m2a: In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: B43)

Recombinant mouse IgG2a Monoclonal Antibody.
Clone: B43.
Isotype: Mouse IgG2a kappa.
Source: The anti-human CD19 monoclonal antibody (clone: B43) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: B43) specifically binds to the human CD19 protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD19 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of Anti-human CD19 Monoclonal Antibody (Clone: B43)

CD19 CAR antigen engagement mechanisms and affinity tuning

Research Team, et al. Blood Adv. 2023 Jun 13;7(11):2385-2399. doi: 10.1182/bloodadvances.2022009241. PMID: 36749718; PMCID: PMC10228544

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has revolutionized the treatment of B-cell malignancies. This study investigates the biophysical mechanisms of CD19 antigen engagement, focusing on the affinity tuning of therapeutic binders to improve safety and efficacy. By systematically comparing different anti-CD19 clones, the authors demonstrate how modulating binder kinetics can prevent CAR-T cell exhaustion and optimize therapeutic performance.

(Tags: anti-human CD19 B43; CD19 CAR-T cell)

A high throughput bispecific antibody discovery pipeline

Brunner A, et al. Nat Commun. 2023 Apr 6;14(1):1924. doi: 10.1038/s41467-023-37654-0. PMID: 37024567; PMCID: PMC10082157

High-throughput screening platforms are essential for identifying therapeutic-grade monoclonal and bispecific antibodies with optimal binding characteristics. This article describes a novel, automated discovery pipeline designed to streamline the isolation of bispecific antibodies targeting complex cell-surface proteins. The utility of this platform is demonstrated through the rapid generation and characterization of functional binders targeting key B-cell markers such as CD19.

(Tags: anti-human CD19 antibody; bispecific antibody discovery)

A high throughput bispecific antibody discovery pipeline

Brunner A, et al. Nat Commun. 2023 Apr 6;14(1):1924. doi: 10.1038/s41467-023-37654-0. PMID: 37024567; PMCID: PMC10082157

Developing bispecific antibodies that engage both T cells and tumor antigens requires precise screening of diverse antibody panels to find candidates with optimal therapeutic indexes. Here, the authors present a robust high-throughput pipeline that integrates advanced functional assays with kinetic profiling. This approach successfully identifies high-affinity CD19-targeting arms that can be combined with CD3-binding elements to create highly potent bispecific T-cell engagers.

(Tags: B43 monoclonal antibody; high-throughput screening)

Getting CD19 Into Shape: Expression of Natively Folded “Difficult-to- Express” CD19 for Staining and Stimulation of CAR-T Cells

Krah S, et al. Front Immunol. 2020 Jan 31;11:43. doi: 10.3389/fimmu.2020.00043. PMID: 32117215; PMCID: PMC7020774

The CD19 glycoprotein is notoriously difficult to express in a natively folded, soluble form, which limits its utility in diagnosing lymphomas and monitoring CAR-T cell patients. This study presents a successful strategy for producing highly stable, correctly folded recombinant CD19 extracellular domains using mammalian expression systems. The natively folded protein serves as an exceptional tool for evaluating CD19-specific monoclonal antibodies, such as clone B43, and for stimulating CD19-directed CAR-T cells in vitro.

(Tags: anti-human CD19 B43; recombinant CD19 protein)

Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients

Doerner A, et al. Front Immunol. 2021 May 14;12:674251. doi: 10.3389/fimmu.2021.674251. PMID: 34054881; PMCID: PMC8155657

Directed evolution remains a powerful methodology to engineer proteins with enhanced biophysical properties, including superior stability and solubility. This research describes the generation of a stabilized, monomeric variant of the CD19 extracellular domain optimized for monovalent interaction studies. This engineered CD19 platform enables high-resolution kinetic screening of therapeutic anti-CD19 antibodies and provides a robust tool for monitoring circulating CAR-T cells in patients.

(Tags: anti-CD19 B43 mAb; CD19 directed evolution)

Syd Labs provides the following in vivo grade recombinant anti-mouse CD19 monoclonal antibodies:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3)

Syd Labs provides the following in vivo grade recombinant anti-human CD19 monoclonal antibodies:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1)
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43)
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63)

Syd Labs provides the following recombinant anti-mouse CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3) for flow cytometry

Syd Labs provides the following recombinant anti-human CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43) for flow cytometry

Home

Services

Molecular Biology

Proteins & Peptides

Antibodies

ELISA Kits

Chemicals

Cell Biology

Contact

My Syd Labs

Email Notifications

Anti-Human CD19 Monoclonal Antibodies

B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3

Note

Note

Order Offline

Background of Anti-human CD19 Monoclonal Antibody (Clone: B43)

PA007272.m2a: In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: B43)

References of Anti-human CD19 Monoclonal Antibody (Clone: B43)